DiaMedica Therapeutics Q3 loss widens on higher R&D costs
DMAC•DMAC•DMAC•DMAC•DiaMedica Therapeutics’ third-quarter net loss widened year over year to $11.31 million, above the $10.96 million analyst estimate, while its $0.21 loss per share matched expectations. The company had $34.9 million in cash and investments and expects its cash to fund operations into Q4 2027.
DiaMedica Therapeutics reported a third-quarter net loss of $11.31 million, compared with an analyst consensus estimate of $10.96 million. Loss per share was $0.21, in line with estimates.
Higher research and development expenses reflected expansion of the clinical team, the ongoing ReMEDy2 trial, start-up of a Phase 2 preeclampsia trial, additional toxicity testing and increased manufacturing activity. The company expects research and development expenses to moderately increase as clinical trials progress; it expects the ReMEDy2 interim analysis in acute ischemic stroke to be completed in Q1 2027 and said current cash should fund operations into Q4 2027.
